Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced a conference call on May 11, 2021, to discuss Q1 2021 business updates. The call will feature CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. Interested participants can join via webcast or telephone after registering. Innate Pharma focuses on oncology and boasts a diverse pipeline of therapeutic antibodies designed to improve cancer treatment outcomes. Its partnerships with leading biopharmaceutical companies enhance its research capabilities in this sector.
Innate Pharma has filed its 2020 Universal Registration Document with the French AMF and its annual report on Form 20-F with the SEC. Both documents are accessible on the company's website. Innate focuses on oncology with a pipeline of therapeutic antibodies aimed at improving cancer treatments. The company has established significant alliances with major biopharmaceutical firms, enhancing its research capacity. However, the press release warns of risks associated with R&D, clinical trial uncertainties, and potential impacts from COVID-19 on operations.
Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced the filing of its 2020 Universal Registration Document with the French market authority, AMF, and its annual report on Form 20-F with the SEC. Both documents are available on the company’s and the respective authorities' websites. Innate Pharma is a clinical-stage biotech company focused on oncology, with a diverse pipeline of therapeutic antibodies aimed at improving cancer treatment. The company collaborates with major biopharmaceutical firms, enhancing its market position.
Innate Pharma will hold its Annual General Meeting (AGM) on May 28, 2021, at 11:00 a.m. CET. The meeting will be broadcasted live, allowing shareholders to participate via mail or proxy due to health-related restrictions on gatherings.
Shareholders must register their shares two business days before the AGM to vote. Written questions are welcomed until two business days prior, and connection details will be available on the company’s website. For more information, documentation will be accessible through their investor relations email.
Innate Pharma has disclosed its share capital structure as of April 1, 2021. The company has a total of 78,996,240 ordinary shares outstanding, along with 6,806 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 79,799,621, while 79,781,046 are exercisable. This information complies with the French stock market regulations to ensure market transparency.
Innate Pharma focuses on cancer treatment through therapeutic antibodies and partners with major biopharmaceutical firms.
Innate Pharma reported financial results for 2020, revealing a revenue decline of 17.9% to €70.5 million, attributed mainly to a drop in collaboration income from AstraZeneca. The company faced a net loss of €64 million, up from €20.8 million the previous year, partly due to a €43.5 million impairment on Lumoxiti assets after returning commercialization rights to AstraZeneca. Despite challenges, Innate achieved significant milestones, including PRIME designation for lacutamab and a Phase 3 trial startup for monalizumab, contributing to a cash position of €190.6 million by year-end.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) will hold a conference call on March 18, 2021, at 2 p.m. CET / 9 a.m. ET to discuss its financial results for the year ending December 31, 2020. Key executives, including CEO Mondher Mahjoubi and CFO Laure-Hélène Mercier, will provide insights during the call. Participants can join the call via a live webcast or telephone registration, with a replay available for 90 days. Innate Pharma is focused on oncology and has partnerships with major biopharmaceutical firms, emphasizing its commitment to innovative cancer treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its total number of shares outstanding as of February 1, 2021. The company has 78,989,740 ordinary shares, including 6,856 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights is 79,799,621, while the exercisable voting rights stand at 79,781,046. This disclosure complies with French regulation and emphasizes Innate Pharma's commitment to keeping investors informed regarding shareholding positions and governance.
Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced that its senior management will participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24-26, 2021. A fireside chat is scheduled on February 24 from 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ET. The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-event. Innate Pharma focuses on oncology and uses therapeutic antibodies to enhance cancer treatment, collaborating with major biopharmaceutical companies.
Innate Pharma SA (Nasdaq: IPHA) announced significant progress in clinical development for lacutamab, an anti-KIR3DL2 antibody targeting T-cell lymphomas. The KIR3DL2-expressing mycosis fungoides cohort in the TELLOMAK trial has advanced to Stage 2 ahead of schedule, with preliminary positive results prompting further recruitment. Additionally, two new trials will investigate lacutamab's efficacy in peripheral T-cell lymphoma, including a Phase 2 study in collaboration with LYSA. These developments suggest a strategic push into earlier lines of therapy and enhancement of treatment options for patients.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
